Posted by [ad_1]
Arbutus Biopharma (NASDAQ:ABUS) announced on Monday its 2025 corporate objectives and provided a financial update. The company had cash, cash equivalents and investments in marketable securities totaling approximately $123 million as of December 31, 2024.
The company expects to significantly
[ad_2]